• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    PCI Pharma Services

    Reed-Lane

    Syngene

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Emergent BioSolutions

    Aphena Pharma Solutions

    PCI Pharma Services

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Biosimilars Update

    Fulfilling a dire need, but at what (human) cost?

    Related CONTENT
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • CDMO Stelis Continues Expansion
    • Mogene
    • Stelis BioSource Continues Facility Investment
    • Rising to The Occasion: The High Stakes of Vaccine Transport
    Ben Locwin, Contributing Editor04.03.17
    There is currently a market void for oncology products, where demand has outstripped supply, and there are millions of patients and soon-to-be-diagnosed new patients who are in need of these treatments. Add to this that certain biotherapeutic oncological immunomodulators are also being used off-label and experimentally for a variety of conditions such as arthritis, certain thyroid diseases, dermatologic conditions, and many others. This puts a further draw on the supply side, increasing the deficit of treatment availability on the demand side. How might biosimilars fill this void? And what are future-looking concerns that we should remain vigilant toward?

    Current oncology landscape
    There are currently over 200 drug treatments for cancer available to patients in the U.S., according to the NIH National Cancer Institute. There are also approximately 4,600 new cases of cancer diagnosed every day, which means that patient demand will not abate.

    Of these treatments, there are sporadic shortages of antibody therapies of different types. But this seems to be just where the biosimilars market is best designed to fit in. That is, with recently innovated treatments, which have high demand by the consumer market, but whose patients aren’t able to access the branded therapies either due to shortfalls of availability or prohibitiveness of cost. If these conditions could have wide access to biosimilars, the number of treated patients compared with today would increase by tens of millions per year worldwide. With average survivability improvements owing to the treatments of several months to years, and favorable Quality-Adjusted Life Years (QALY) profiles, this helps improve the world’s battle with cancer to the tune of hundreds of millions to tens of billions of human-years added annually across the globe. But let’s look at some of the downside risk of this proposition.

    Approval status of biosimilars as a whole
    While still considered ‘new,’ biosimilars aren’t a new approach to therapies, but are more accurately described as still being a nascent industry. This is because the regulatory track record is still immature—only a handful of approvals—and being built, mostly by the continued and diligent hard work applied by the top companies producing these drugs and working with regulatory authorities on stabilizing the requirements. But it almost is a situation of optimism slowing market availability, and ‘perfection’ being the enemy of ‘good enough.’

    Because the vast majority of polled respondents in the industry feel that biosimilars offer a wealth of benefits and value to the market, it has almost become assumed common knowledge that the future will bring a whole host of biosimilar treatments. But this optimism has also contributed to overconfidence and a loss of focus for some treatments in the biosimilar pipeline. By the very nature of biosimilars being associated with approved treatments and the success of generics for small molecule therapies, there has been an expectation that they’ll ‘just work’ and fly through regulatory approval. Consequently, there hasn’t been the same level of problem-solving and regulatory risk-reduction being implemented in all cases of biosimilar production.

    I’ve brought into pharma a few cognitive traps from work I’ve done in other industries that lead to these overestimations and delays in market approval, which, by the way, come at a cost of hundreds-of-thousands to tens-of-millions in opportunity cost (USD) per day of delay.

    Heuristics
    Often used in computer programming to describe certain shortcuts, we have identified a number of psychological heuristics that operate in people, which in general tend to help us navigate our daily lives, but in certain cases can have extraordinarily dire consequences. These ‘rules of thumb’ are mental shortcuts that our brains use to keep from spending too much cognitive resources on generalizable and routine tasks; unfortunately, a ‘Familiarity’ heuristic prevents us from allowing new information in to potentially change our course of action. Ian McCammon analyzed some of these heuristics in the field of avalanche research and found that groups with advanced training in terrain that they were familiar with exposed themselves to nearly twice the hazard level of less well-educated groups, and about the same level of hazard as parties with no avalanche training at all.

    Another significant cognitive bias is the ‘Consistency’ heuristic, which states that once on a particular course of action, how often have you seen teams actually overcome the momentum and intertia of a bad decision and make radical changes to the outcome to guarantee success? It’s actually quite rare, especially with more money and time committed to the project(s). The consistency heuristic keeps us moving on a similar path, presumably to avoid distractions and limit mental energy when distractions surround us. Research into this heuristic has shown that the level of commitment to an end goal, divorced from probabilities of success, were related to the inability to change course. Also, groups of 3 or more people, and within which there has been some level of formal training, are most susceptible to this effect of ‘staying the course.’

    How similar?
    In the medical device industry, there are special provisions and determinations made for ‘substantial equivalence,’ as a specific example, for a 510(k) premarket notification application, that the new device is at least as safe and effective as the predicate (device). Biosimilars have to demonstrate similarity with their innovator compound (predecessor), though how similar has been a moving target.

    For biosimilars, FDA lists the following: To have a product reviewed as a biosimilar or interchangeable, manufacturers must submit a 351(k) biologics license application (BLA) that includes, among other things, information demonstrating biosimilarity based upon the following:
    • Analytical studies demonstrating that the biological product is “highly similar” to the reference product notwithstanding minor differences in clinically inactive components;
    • Animal studies (including the assessment of toxicity); and
    • A clinical study or studies (including the assessment of immunogenicity and pharmacokinetics (PK) or pharmacodynamics (PD)) sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and for which licensure is sought for the biosimilar product.
    I wonder about the ‘substantial equivalence’ in these cases and how “highly similar” is enough, specifically in treatments for significant disease or disorders where there is no availability of the innovator compound either because of market shortages or regional approval, or it is too expensive. For people with zero other net options, it seems beneficial to have the biosimilars widely available, but at what (human) cost? A recent review published by MedPage Today and the Milwaukee Journal Sentinel found that drug side effects reporting from the public to the FDA has skyrocketed by 500% between 2004 and 2015. And in particular cases (Zecuity migraine patch), the FDA allowed market release as long as the manufacturer reported AEs to the agency within 15 days of receiving a complaint. Effectively, this was moving the phase III trial out to Main Street.

    What similar sorts of medical burden could be caused by favoring the balance of availability over rigorous safety and equivalence testing? And of course, the challenge for the regulatory agencies is also the flip side: Testing ad infinitum means that populations may be needlessly suffering without a viable treatment option available that may exist, because it is caught up in excessive review bureaucracy. Lyndsay Meyer, an FDA spokeswoman, thinks this is all part of evolving methods. She said, “It’s not always necessary to wait and go through a traditional development program before making drugs available to patients.”

    For those attending the PDA Annual Meeting this month, or AAPS’ National Biotechnology Conference 2017, these are high-impact discussion points I’d love to get your thoughts and input on. After all, we’re at a place in time right now that will be looked at as history in our future: We are shaping how we want this period of time to be remembered, with respect to biosimilars and other issues in the industry. Let’s make the smartest and most-informed decisions that we collectively can. 

    References
    1. McCammon, I. (2004). Heuristic traps in recreational avalanche accidents: Evidence and implications. Avalanche News, 68.
    2. Herbert, W. (2010). On second thought: Outsmarting your mind’s hardwired habits.

    Ben Locwin
    Contributing Editor

    Ben Locwin, PhD, MBA, MS has worked on drug safety and efficacy of gene therapies, biologics, and small molecules. He has also designed cost models for biosimilars used by Wall Street and industry firms. He is an expert media contact for the American Association for Pharmaceutical Scientists (AAPS) and a Healthcare expert with the Association for Talent Development (ATD). He has been featured by the Associated Press, The Wall Street Journal, and Forbes. He can be reached for questions or advice at Ben.Locwin@HealthcareScienceAdvisors.com.
    Related Searches
    • biosimilar
    • it
    • biotechnology
    • generics
    Suggested For You
    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021 The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    CDMO Stelis Continues Expansion CDMO Stelis Continues Expansion
    Mogene Mogene
    Stelis BioSource Continues Facility Investment Stelis BioSource Continues Facility Investment
    Rising to The Occasion: The High Stakes of Vaccine Transport Rising to The Occasion: The High Stakes of Vaccine Transport
    Financial Report: Pfizer Financial Report: Pfizer
    Pharmaceutical Excipients Market Poised for Growth Pharmaceutical Excipients Market Poised for Growth
    Financial Report: Biogen Financial Report: Biogen
    BryoLogyx Completes World’s First GMP Synthesis of Bryostatin-1 BryoLogyx Completes World’s First GMP Synthesis of Bryostatin-1
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    Indian Generic Firms  Expand Biosimilar Portfolios Indian Generic Firms Expand Biosimilar Portfolios
    So You Think You Know  All About Excipients? So You Think You Know All About Excipients?
    The FDA and Metrics The FDA and Metrics
    Biomanufacturing Trends and Outlook 2017: Where Is It All Going? Biomanufacturing Trends and Outlook 2017: Where Is It All Going?
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.

    Related Columns

    • Biosimilars
      The Bioprocessing Trek

      The Bioprocessing Trek

      Biosimilars are the next speed-bump for CMOs
      Emil W. Ciurczak, DoraMaxx Consulting 09.16.19

    • Biosimilars
      Know the Challenges of  Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best practices for a competitive market
      Jerry Martin and Michiel Ultee 09.06.17

    • Biosimilars
      Indian Generic Firms  Expand Biosimilar Portfolios

      Indian Generic Firms Expand Biosimilar Portfolios

      With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India
      S. Harachand, Contributing Editor 05.09.17


    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17

    • Biosimilars | Process Development

      Contract Manufacturing Budget Trends

      Study shows where the money is, and isn’t, flowing
      Eric S. Langer, BioPlan Associates 07.12.16

    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16


    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars | Clinical Trials | Process Development | Vials

      2015 in Review: 6 Key Trends Affecting CMOs

      A look at major CMO trends ranging from budgets to growth opportunities
      Eric S. Langer, BioPlan Associates 11.17.15

    • APIs | Biosimilars

      API and Intermediate Outsourcing Trends

      One thing’s for sure, when it comes to pharma trends there is no definitive trend
      Ben Locwin, Healthcare Science Advisors 10.07.15


    • Biosimilars | Fill/Finish | QA/QC

      CMOs Are Willing to Pay for More Innovation

      Downstream improvements top the list
      Eric S. Langer, BioPlan Associates 09.11.15

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15

    • Biosimilars | GMPs/GCPs | Inspections | Regulatory Affairs

      Biosimilars and Their Future in Medicine

      The first step is understanding what biosimilars actually are
      Ben Locwin, Healthcare Science Advisors 06.02.15


    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    • Biosimilars | Methods Development | Process Development | Supply Chain | Validation

      CMOs Demanding Easier-to-Integrate Single-use Devices

      Disposables’ implementation and integration critical; suppliers being put on notice
      Jean-Claude Lupis and Eric S. Langer, BioPlan Associates 05.06.15

    • APIs | Biosimilars | Process Development | Supply Chain

      Biosimilars Improving Efficiency, Cost for All Biologics

      ...
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.01.15

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    John Masters Organics Rolls Out Roll-On Fragrances
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login